Thank you for all the support during #APLAR25❤️ Grateful to be part of this amazing team! Hoping for the community to keep growing🌸 #AYR #APLAR #SoMe @rheumarhyme 🔗 https://t.co/zl5WuR5dha

✅ Check my summary slide for the Phase 3 trial result of #Telitacicept (dual inhibitor of BLyS and APRIL) in systemic #lupus ⬇️ Link to the NEJM publication: https://t.co/AvUqKoKOkF

NEW! The ACR just released an updated clinical practice guideline for #SLE! Key recommendations include universal hydroxychloroquine use, lower steroid exposure, & earlier immunosuppressive therapy. Patient-centered care is central. READ MORE → https://t.co/wRUuS5p2HG

🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @UNMC_Rheum 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumX #RheumTwitter #ACR2025

🆕 ACR 2025 Guidelines for Treatment of Systemic Lupus Erythematosus #ACR25 #Lupus #RheumTwitter

🧵 Thread: The 2025 Breakthroughs in Basic Science (ACR Convergence)🌎 ⭐️⭐️From gene editing to AI in drug discovery — check out these 6 core updates reshaping rheumatology and translational medicine this year!!👇 #ACR25 #ACRambassador

SLE and Osteoporosis | RheumNow 🦋🦴 ⁦@RHEUMarampa⁩ ❤️ ⁦@RheumNow⁩ ⁦⁦@APLAR_org⁩ #aplar25 #aplar #ayr #lupus #SLE

APLAR 2025: What’s New in RA Management? | RheumNow ⁦@AurelieRheumo⁩ #aplar25 ⁦ @APLAR_org⁩ ⁦@RheumNow⁩

And it’s a wrap! Thanks @APLAR_org for a fantastic conference I had a fantastic time in Fukuoka ⭐️ Networking with colleagues from all over the world 🌎 ⭐️ Reporting for @RheumNow with @RHEUMarampa ⭐️ Making Japanese lanterns, origami and singing karaoke 🎤 ⭐️ Climbing

It’s a wrap! Thank you for a wonderful #APLAR25 conference 😀 ✅ New learnings ✅ Reported for @RheumNow with @AurelieRheumo ✅ Met new friends F2F @ori_114 ✅ Connected w/🇵🇭 & international rheums from @APLAR_org @rheumarhyme

Recap, Day2📷 Thank you all for joining us at the AYR booth😊❣️ #aplar25 #AYR #JSTAR @APLAR_org @JCRheum

Dr. Alberta Hoi graphically presents the difference bet acute confusional states & chronic cognitive changes in #lupus patients presenting with NP symptoms. NPSLE continues to pose a diagnostic challenge bec pts may present with more than one syndrome complex @RheumNow #APLAR25

President Dr Paulo Lorenzo closes the 27th APLAR Congress with his message to advance rheumatology improving and inspiring lives thru unity in diversity 🌐 #APLAR2025 #APLAR25

✅ Strikingly ~40% of all active investigational #trials in #SLE assess a type of cellular therapy, of which anti-CD19 #CART represents the highest proportion, among various other targets and and targeting constructs ⬇️ #APLAR25

✅ What are the main goals of #Rheumatology specialists when treating systemic #Lupus in 2025? Our aim is mostly to attain - and then maintain - #remission, with many other favorable outcomes associated with this state👌the longer the better 🙏 #APLAR25

APLAR 2024 guidelines for LN: Standard dose IV Cyclo as 1st-line IS instead of low-dose Cyclo for Asian patients (tend to have more severe disease). #APLAR2025 #APLAR25

A new player in AIRD ThA age associated T helper cells Displaying both Cytotoxic & APC functions Correlation with disease activity in RA and SLE More research is needed to better characterize function but could be a promising therapeutic target @RheumNow #APLAR25

It was great start with morning run! #APLAR25

An important message from Prof. @XBaraliakos on D2M-axSpA: Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage. consider other causes: FM, other causes of pain @RheumNow #APLAR25 @rheumarhyme @marklagacmd

#APLAR25 #singlecellomics by Prof Nishide does amazing work! #connecting clinical disease classification and #biomarker difference #citeseq #EGR1 as biomarker #monocyte #MPA #bedside #phenotypestratification #MPA-mono #MPA-IFN #spatialtranscriptomics #SRC #fibrosispathway #ANCA